CovidChloroV1, Main, Corpus, bibRecord, 001535

Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al.

Identifieur interne : 001535 ( Main/Corpus ); précédent : 001534; suivant : 001536

Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al.

Auteurs : Maximilian F. Konig ; Milena Gianfrancesco ; Jinoos Yazdany ; Philip C. Robinson

Source :

Annals of the rheumatic diseases [ 1468-2060 ] ; 2020.

RBID : pubmed:32475834
DOI: 10.1136/annrheumdis-2020-217990
PubMed: 32475834
PubMed Central: PMC7704575

Links to Exploration step

pubmed:32475834

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon <i>et al</i>
.</title>
<author><name sortKey="Konig, Maximilian F" sort="Konig, Maximilian F" uniqKey="Konig M" first="Maximilian F" last="Konig">Maximilian F. Konig</name>
<affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gianfrancesco, Milena" sort="Gianfrancesco, Milena" uniqKey="Gianfrancesco M" first="Milena" last="Gianfrancesco">Milena Gianfrancesco</name>
<affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yazdany, Jinoos" sort="Yazdany, Jinoos" uniqKey="Yazdany J" first="Jinoos" last="Yazdany">Jinoos Yazdany</name>
<affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name>
<affiliation><nlm:affiliation>Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32475834</idno>
<idno type="pmid">32475834</idno>
<idno type="doi">10.1136/annrheumdis-2020-217990</idno>
<idno type="pmc">PMC7704575</idno>
<idno type="wicri:Area/Main/Corpus">001535</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001535</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon <i>et al</i>
.</title>
<author><name sortKey="Konig, Maximilian F" sort="Konig, Maximilian F" uniqKey="Konig M" first="Maximilian F" last="Konig">Maximilian F. Konig</name>
<affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gianfrancesco, Milena" sort="Gianfrancesco, Milena" uniqKey="Gianfrancesco M" first="Milena" last="Gianfrancesco">Milena Gianfrancesco</name>
<affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Yazdany, Jinoos" sort="Yazdany, Jinoos" uniqKey="Yazdany J" first="Jinoos" last="Yazdany">Jinoos Yazdany</name>
<affiliation><nlm:affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name>
<affiliation><nlm:affiliation>Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of the rheumatic diseases</title>
<idno type="eISSN">1468-2060</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32475834</PMID>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>May</Month>
<Day>31</Day>
</PubDate>
</JournalIssue>
<Title>Annals of the rheumatic diseases</Title>
<ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon <i>et al</i>
.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">annrheumdis-2020-217990</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2020-217990</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konig</LastName>
<ForeName>Maximilian F</ForeName>
<Initials>MF</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-5045-5255</Identifier>
<AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA konig@jhmi.edu philip.robinson@uq.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gianfrancesco</LastName>
<ForeName>Milena</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yazdany</LastName>
<ForeName>Jinoos</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Robinson</LastName>
<ForeName>Philip C</ForeName>
<Initials>PC</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-3156-3418</Identifier>
<AffiliationInfo><Affiliation>Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia konig@jhmi.edu philip.robinson@uq.edu.au.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>T32 AR048522</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Ann Rheum Dis</MedlineTA>
<NlmUniqueID>0372355</NlmUniqueID>
<ISSNLinking>0003-4967</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">epidemiology</Keyword>
<Keyword MajorTopicYN="N">hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword>
</KeywordList>
<CoiStatement>Competing interests: None declared.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>05</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pmc-release"><Year>2021</Year>
<Month>11</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32475834</ArticleId>
<ArticleId IdType="pii">annrheumdis-2020-217990</ArticleId>
<ArticleId IdType="doi">10.1136/annrheumdis-2020-217990</ArticleId>
<ArticleId IdType="pmc">PMC7704575</ArticleId>
<ArticleId IdType="mid">NIHMS1604769</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lupus. 2001;10(6):401-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11434574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Oct;79(10):1386-1388</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32381561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2006 Nov;54(11):3640-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17075810</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 2015 Feb;24(2):210-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25305214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2020 Jul;79(7):859-866</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32471903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2009 Feb;68(2):238-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18782792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2017 Mar;76(3):476-485</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27457513</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheumatol. 2020 Apr;72(4):529-556</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32090480</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001535 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001535 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32475834
   |texte=   Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32475834" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021